Drug R&D and Transformation CXO Whole Industry Chain Innovation The service forum is a complete success, and the new leadership opens a new era of CXO in an all-round way!
On September 27th, the "Sub-Forum 5 of the Second Zhengzhou International Biomedical Development Summit Forum-CXO Innovation Service Forum of Pharmaceutical R&D and Transformation Industry Chain", jointly sponsored by the Pharmaceutical Chamber of Commerce of All-China Federation of Industry and Commerce, R&D and Transformation Service Professional Committee of China Food and Drug Enterprise Quality and Safety Promotion Association, and Shenzhen Shenlanhai, a new leader in Beijing, was a complete success! Experts, scholars and enterprise representatives gathered together to discuss the development direction of CXO's innovative service in the whole industrial chain, and help the innovation and development of China's biomedical industry.
Major General Wang Yumin, former Deputy Minister of Health of General Logistics Department, Professor Hu Changqin, Chief Expert of Chemical Drug Testing of China Food and Drug Testing Institute, Mr. Du Guanhua, Vice President of Pharmaceutical Research Institute of Peking Union Medical College of Chinese Academy of Medical Sciences and Director of National Drug Screening Center, Mr. Wang Bo, President of Beijing Qinmai Pharmaceutical Technology Development Co., Ltd., and Mr. Lu Donghong, Technical Deputy Director of Pharmaceutical Chamber of Commerce of All-China Federation of Industry and Commerce. Mr. Tao Xinhua, Chairman of Beijing New Leading Pharmaceutical Science and Technology Development Co., Ltd., Ms. Gao Shijing, President of Beijing New Leading Pharmaceutical Science and Technology Development Co., Ltd., and representatives of some vice-presidents of the Chamber of Commerce and Industry of the Federation of Industry and Commerce attended the meeting.
The meeting was co-chaired by Ms. Zhou Meiyin, Chairman of Beijing Excellence Future International Medical Technology Development Co., Ltd. and Mr. Zhang Ronghuo, Vice President of Beijing New Leading Medical Technology Development Co., Ltd..
Major General Wang Yumin said in his speech that at present, there is still a certain gap between the domestic clinical trial level and the international advanced level, and there is also a great demand for new drug research and development. The third-party CRO service company, by closely combining the innovation chain, service chain and industrial chain, provides guarantee for new drug research and development, provides support for accelerating the listing of drugs, continuously improves the quality of drug research and development, continuously provides patients with new drugs and good drugs, and makes great contributions to the development of the industry. General Wang especially affirmed the contribution made by the new leading CXO integrated service system in the fields of new drug research and development and clinical trials.
Mr. Lu Donghong and Mr. Wang Bo congratulated the conference on its smooth convening, expressed their full expectation for CXO system, and commented on centralized mining and the latest laws and regulations.
Associate Dean, Institute of Medicine, Peking Union Medical College, Chinese Academy of Medical Sciences
《Clinical Pharmacology Development and New Drug Research and Development》
President of Beijing New Leading Pharmaceutical Technology Development Co., Ltd.
《Interpretation of CXO and New Leading Practice》
Chief Expert of Chemical Drug Verification in China Food and Drug Verification Research Institute
《Discussion on Key Technologies Affecting Evaluation of Injection Consistency》
Deputy Director of Zhongguancun Lianchuang Medical Engineering Transformation Center
《Building Ecology to Help Medicine R&D Innovation Transformation》
Director of Pharmacy Department, Fifth Affiliated Hospital of Guangzhou Medical University
《Comparative interpretation of the new and old versions of
Vice President of Zhejiang Teresi Pharmaceutical Co., Ltd.
《Based on Understanding, Derived from Design —— Discussion on Factors of Clinical Research Results of New Cancer Drugs》
Deputy Director of Shimadzu China Innovation Center
New Technology and Efficient Quality Control of Antibiotic Polymer Impurity Analysis under the New Review Form
The new leading CXO service system was born, which brought infinite surprises and imagination to the medical field. The new leader also hopes to work with colleagues in the industry to continuously expand the CXO whole industry chain service system, empower innovative enterprises to break through the bottleneck and grow at a high speed in a multi-dimensional and all-round way, comprehensively help the innovation and development of China's pharmaceutical industry, and jointly build a world-class leading enterprise!
Introduction to the conference
From September 26th to 27th, the Second Zhengzhou International Biomedical Development Summit Forum was successfully held in Zhengzhou Airport Biomedical Park. The theme of this event is "Creating the Future in Caihui Port Area", which is mainly divided into the opening ceremony, the main forum of the conference and five theme sub-forums. The forum uses the form of conference report and round-table discussion to convene the leading figures in the domestic biomedical field. Focusing on the global pattern of innovative drug research and development, the research and application of cell/gene therapy, the new leading CXO (whole industry chain service outsourcing) model, policies and regulations, and capital assistance, etc., discuss the most cutting-edge industry progress and
More than 500 leading experts and scholars gathered in the conference to discuss the frontier theory and development achievements of biomedical industry. Chen Kaixian, academician of Chinese Academy of Sciences, Zhang Gaiping, academician of Chinese Academy of Engineering, Zhu Xun, chairman of Tongxiyi New Drug Talent Club, and Zhang Yuntao, vice president of Sinopharm China Biotechnology Co., Ltd. made keynote speeches respectively, and analyzed and prospected the development of innovative drugs in China under the post-epidemic background.